Efficacy and safety of percutaneous life support during high-risk percutaneous coronary intervention, refractory XXXX and in-laboratory cardiopulmonary arrest.

@entity1 @entity455 @entity548 @entity7541 @entity1167 @entity1455
BACKGROUND: High-risk percutaneous coronary interventions (PCI), refractory @entity1455 and in-lab @entity1167 are all associated with significant mortality. Percutaneous left ventricular assist devices (pLVAD) and @entity1167 ( @entity1167 ) have been used to support such @entity1 . However, the extent to which the use of these devices can improve outcomes in this @entity1 subset is not known. METHODS: We evaluated clinical features, efficacy and safety outcomes in a retrospective cohort of 39 @entity1 , treated either with pLVAD or @entity1167 for support of high-risk PCI, @entity1455 or in-lab @entity1167 . The Tandem-Heart and a new versatile Multifunctional Percutaneous Heart ( @entity7541 ) system, with both @entity1167 and LVAD capability, were used and assessed. RESULTS: 19 @entity1 received the TandemHeart and 20 received the @entity7541 system. The @entity7541 system was used as a pLVAD in 12 and to provide @entity1167 in 8 @entity1 . Procedural efficacy was 100%. Emergent institution of @entity1167 , in the setting of @entity1167 , was able to support 7 out of 8 @entity1 and resulted in a 50% survival to hospital discharge rate. Overall, in-hospital death and 30-day major adverse cardiac event rates were 28.2% and 35.9%, respectively. The risk of @entity455 and @entity548 was relatively small. CONCLUSIONS: pLVADs are effective in supporting @entity1 during high-risk cardiac (coronary and structural heart) interventions, with a low risk of device-related complications. Further, the expeditious use of @entity1167 in the catheterization laboratory can improve survival in a selected subset of @entity1 with refractory @entity1455 and @entity1167 .
